Is Retatrutide Actually Worth It?

Weight loss is the headline. It is not the story.

In May 2026, Eli Lilly announced Phase 3 results showing participants lost an average of 28.3% of body weight at 80 weeks — the highest sustained pharmacological weight loss ever recorded in a major clinical trial.

But here's what most guides don't tell you: retatrutide is currently in eight separate Phase 3 trials covering eight separate conditions — liver disease, joint pain, sleep apnea, cardiovascular and kidney outcomes, type 2 diabetes, chronic low back pain. That doesn't happen to weight loss drugs. It happens to something doing far more than moving the number on the scale.

This guide covers the mechanism behind all of it — the third receptor no other approved compound targets — plus the Phase 2 and Phase 3 numbers exactly as published, no exaggeration.